The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow.

Autor:	Lorenzini L; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands. Electronic address: l.lorenzini@amsterdamumc.nl., Ingala S; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands., Wink AM; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands., Kuijer JPA; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands., Wottschel V; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands., Dijsselhof M; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands., Sudre CH; MRC Unit for Lifelong Health and Ageing at UCL, London, UK; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; Centre for Medical Image Computing, University College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, UK., Haller S; CIMC - Centre d'Imagerie Médicale de Cornavin, Place de Cornavin 18, 1201 Genève, Switzerland; Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden., Molinuevo JL; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; H. Lundbeck A/S, 2500 Valby, Denmark., Gispert JD; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona Spain; Universitat Pompeu Fabra, Barcelona, Spain; CIBER Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain., Cash DM; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; UK Dementia Research Institute, University College of London, London, UK., Thomas DL; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology London, UK; Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, London, UK., Vos SB; Centre for Medical Image Computing, University College London, London, UK; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology London, UK., Prados F; Nuclear Magnetic Resonance Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, United Kingdom; e-Health Centre, Universitat Oberta de Catalunya, Barcelona, Spain., Petr J; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany., Wolz R; IXICO, London, UK; Imperial College London, London, UK., Palombit A; IXICO, London, UK., Schwarz AJ; Takeda Pharmaceuticals Ltd., Cambridge, MA, USA., Chételat G; Université de Normandie, Unicaen, Inserm, U1237, PhIND 'Physiopathology and Imaging of Neurological Disorders', Institut Blood-and-Brain @ Caen-Normandie, Cyceron, 14000 Caen, France., Payoux P; Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France; Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, France., Di Perri C; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK., Wardlaw JM; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at Edinburgh, University of Edinburgh, UK., Frisoni GB; Laboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva, Geneva, Switzerland., Foley C; GE Healthcare Ltd., Little Chalfont, UK., Fox NC; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK., Ritchie C; Centre for Dementia Prevention, The University of Edinburgh, Scotland, UK., Pernet C; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark., Waldman A; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Department of Brain Sciences, Imperial College London, London, UK., Barkhof F; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Institute of Neurology and Healthcare Engineering, University College London, London, UK; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands., Mutsaerts HJMM; Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Ghent Institute for Functional and Metabolic Imaging (GIfMI), Ghent University, Ghent, Belgium; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	NeuroImage. Clinical [Neuroimage Clin] 2022; Vol. 35, pp. 103106. Date of Electronic Publication: 2022 Jul 07.
DOI:	10.1016/j.nicl.2022.103106
Abstrakt:	The European Prevention of Alzheimer Dementia (EPAD) is a multi-center study that aims to characterize the preclinical and prodromal stages of Alzheimer's Disease. The EPAD imaging dataset includes core (3D T1w, 3D FLAIR) and advanced (ASL, diffusion MRI, and resting-state fMRI) MRI sequences. Here, we give an overview of the semi-automatic multimodal and multisite pipeline that we developed to curate, preprocess, quality control (QC), and compute image-derived phenotypes (IDPs) from the EPAD MRI dataset. This pipeline harmonizes DICOM data structure across sites and performs standardized MRI preprocessing steps. A semi-automated MRI QC procedure was implemented to visualize and flag MRI images next to site-specific distributions of QC features - i.e. metrics that represent image quality. The value of each of these QC features was evaluated through comparison with visual assessment and step-wise parameter selection based on logistic regression. IDPs were computed from 5 different MRI modalities and their sanity and potential clinical relevance were ascertained by assessing their relationship with biological markers of aging and dementia. The EPAD v1500.0 data release encompassed core structural scans from 1356 participants 842 fMRI, 831 dMRI, and 858 ASL scans. From 1356 3D T1w images, we identified 17 images with poor quality and 61 with moderate quality. Five QC features - Signal to Noise Ratio (SNR), Contrast to Noise Ratio (CNR), Coefficient of Joint Variation (CJV), Foreground-Background energy Ratio (FBER), and Image Quality Rate (IQR) - were selected as the most informative on image quality by comparison with visual assessment. The multimodal IDPs showed greater impairment in associations with age and dementia biomarkers, demonstrating the potential of the dataset for future clinical analyses. (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu